Increased leukotriene E4 excretion in systemic mastocytosis

被引:40
|
作者
Butterfield, Joseph H. [1 ]
机构
[1] Mayo Clin, Div Allerg Dis, Rochester, MN 55905 USA
关键词
Leukotriene E-4; Mast cells; Systemic mastocytosis; URINARY LEUKOTRIENE-E4; NASAL POLYPOSIS; RECEPTOR; DISEASE; 5-LIPOXYGENASE; ASTHMA; MONTELUKAST; INVOLVEMENT; INHIBITION; CHILDREN;
D O I
10.1016/j.prostaglandins.2010.03.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cysteinyl leukotrienes such as LTE4 are produced by mast cells, neutrophils, eosinophils, and macrophages. LTE4 levels have not been reported in systemic mastocytosis, a disorder with a large increase in mast cell numbers. Urinary LTE4 from patients referred for symptoms potentially due to mast cell degranulation or systemic mastocytosis was measured by a commercial cysteinyl leukotriene enzyme immunoassay kit. The diagnosis of systemic mastocytosis was established using current World Health Organization criteria. Compared with a control group of patients with various potential mast cell-related symptoms (e.g., "spells"), patients with systemic mastocytosis had a significant (P=.01) increase in urinary LTE4 excretion, whether expressed as LTE4 ng/g creatinine or as LTE4 ng/24 h. There was a moderate correlation of LTE4 ng/24 h with excretion of N-methyl histamine and serum tryptase but not with urinary 11 beta-prostaglandin F-2 alpha(11 beta-PGF(2 alpha)) excretion. LTE4 excretion is increased in patients with systemic mastocytosis and potentially contributes to clinical symptoms. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:73 / 76
页数:4
相关论文
共 50 条
  • [31] Immunoaffinity resin for purification of urinary leukotriene E4
    Westcott, JY
    Maxey, KM
    MacDonald, J
    Wenzel, SE
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 1998, 55 (5-6): : 301 - 321
  • [32] Increased levels of urinary leukotriene E4 in children with severe atopic eczema/dermatitis syndrome
    Oymar, K
    Aksnes, L
    ALLERGY, 2005, 60 (01) : 86 - 89
  • [33] Urinary leukotriene E4 levels are not increased prior to high-altitude pulmonary edema
    Bärtsch, P
    Eichenberger, U
    Ballmer, PE
    Gibbs, JSR
    Schirlo, C
    Oelz, O
    Mayatepek, E
    CHEST, 2000, 117 (05) : 1393 - 1398
  • [34] Systemic mastocytosis treated with a leukotriene antagonist
    Milks, CJ
    Beltrani, VS
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (01) : S64 - S64
  • [35] Immunofiltration purification for urinary leukotriene E4 quantitation
    Westcott, JY
    Sloan, S
    Wenzel, SE
    ANALYTICAL BIOCHEMISTRY, 1997, 248 (02) : 202 - 210
  • [36] IMPROVED STRATEGY FOR ANALYSIS OF LEUKOTRIENE E4 IN THE URINE
    KUMLIN, M
    FRANZEN, L
    STENSVAD, F
    DAHLEN, B
    IHRE, E
    LARSSON, C
    BLOMQVIST, H
    ZETTERSTROM, O
    DAHLEN, SE
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (04): : A660 - A660
  • [37] INCREASED EXCRETION OF LEUKOTRIENE-E4 DURING ASPIRIN-INDUCED ASTHMA
    KNAPP, HR
    SLADEK, K
    FITZGERALD, GA
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1992, 119 (01): : 48 - 51
  • [38] Bronchial hyperresponsiveness, hypersensitivity to analgesics and urinary leukotriene E4 excretion in patients with aspirin-intolerant asthma
    Yoshida, S
    Nakagawa, H
    Yamawaki, Y
    Sakamoto, H
    Akahori, K
    Nakabayashi, M
    Sakamoto, M
    Hasegawa, H
    Shoji, T
    Tajima, T
    Amayasu, H
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1998, 117 (02) : 146 - 151
  • [39] Sustained improvement of glycaemic control reduces urinary leukotriene E4 excretion in patients with type 1 diabetes
    Boizel, R.
    Bruttmann, G.
    Benhamou, P. -Y.
    Halimi, S.
    Stanke-Labesque, F.
    DIABETOLOGIA, 2009, 52 : S513 - S514
  • [40] Urinary leukotriene E4 excretion during the first month of life and subsequent bronchopulmonary dysplasia in premature infants
    Sheikh, S
    Null, D
    Gentile, D
    Bimle, C
    Skoner, D
    McCoy, K
    Guthrie, R
    CHEST, 2001, 119 (06) : 1749 - 1754